Latent vs Active TB: What a Positive Skin Test or IGRA Really Tells You

A positive tuberculin skin test or IGRA tells you one thing with confidence: your immune system has met Mycobacterium tuberculosis and remembers it. It does not tell you whether live bacteria are still in your body, whether that encounter was last year or decades ago, or whether you are on your way to becoming ill. Both tests measure immune memory, not active infection, and neither can separate latent tuberculosis infection from active TB disease. Making that separation requires a clinical evaluation, a chest radiograph, and, when indicated, sputum testing.

What the tests actually measure

Tuberculosis testing does not hunt for the bacterium. It reads your body's learned response to it. When immune cells that have previously seen M. tuberculosis antigens encounter them again, they release interferon-gamma and drive inflammation. Both approved test types record that recall response.

The tuberculin skin test injects purified protein derivative, a mixture of mycobacterial proteins, into the forearm. A trained reader measures the raised, firm area of induration 48 to 72 hours later. Interferon-gamma release assays, including the FDA-approved QuantiFERON-TB Gold Plus and T-SPOT.TB, do the same accounting in a tube: blood is mixed with synthetic peptides that mimic specific TB antigens, and the interferon-gamma response is measured.

One signal, two limits

Because IGRAs use antigens (ESAT-6 and CFP-10) that are absent from the BCG vaccine, they are less likely than the skin test to turn positive simply because a person was vaccinated. CDC lists blood tests as the preferred method for people who received the BCG vaccine. But this specificity does not buy what people most want to know. A positive result, by either method, is a marker of sensitization. It says the immune system was trained. It cannot count how many bacteria remain, or whether any remain at all.

Why a positive result cannot tell latent from active

This is the point most often lost. CDC states plainly that a diagnosis of latent TB infection is made when a person has a positive skin or blood test and a medical exam does not indicate TB disease. The test does not make that call. It flags exposure; the workup rules disease in or out.

That is why a positive result triggers an evaluation rather than ending one. Guidance describes the further steps: a chest radiograph and, if disease is suspected, bacteriologic testing of sputum by smear microscopy, culture, and nucleic acid amplification. Those look for the organism itself and the damage it causes. The immunologic tests cannot reliably exclude active disease on their own, which is why anyone with symptoms is evaluated for disease regardless of a test result, and why a negative test never fully clears a sick patient.

Latent and active are ends of a spectrum

The clean split between latent and active is a useful simplification of messier biology. Infection is better pictured as a range: cleared exposure, contained bacteria held in check by immunity, subclinical disease with few or no symptoms, and overt disease. A skin test or IGRA cannot place a person along that range. Two people with identical positive results can sit in very different places, and neither test predicts which way they will move. The label a person eventually receives, latent or active, is assigned after the workup, not read off the test itself.

How progression risk is actually estimated

If the test cannot forecast progression, how is risk judged? Through epidemiology and clinical context, not the test value itself.

The background figure is striking for how modest it is. WHO estimates that about a quarter of the world's population carries immunologic evidence of TB infection, yet only about 5 to 10 percent of infected people ever develop TB disease over a lifetime. Most positive tests never become illness. CDC notes that, in the United States, progression from untreated latent infection nonetheless accounts for roughly 80 percent of TB cases, which is why finding and treating higher-risk infection matters. WHO's 2024 global report underscores the scale behind those percentages, with an estimated 10.8 million people falling ill with TB in a single year.

Risk is concentrated, not uniform. It is highest in the first two years after infection, so a recent conversion, a test that flips from negative to positive after a known exposure, carries more weight than a longstanding positive. It rises sharply with anything that weakens cellular immunity: HIV above all, but also very young age, immunosuppressive therapy, diabetes, undernutrition, and conditions such as silicosis. WHO adds tobacco use and heavy alcohol use to that list. A clinician weighs these factors, the likelihood that the test reflects true infection, and the chest imaging to estimate whether preventive treatment is warranted, since treating latent infection is roughly 90 percent effective at preventing progression.

What a positive test should prompt

A positive result is a beginning. It should lead to a symptom review, a chest radiograph, and an honest accounting of individual risk factors, so that the two questions the test cannot answer, whether active disease is present now and how likely future disease is, get answered by the right tools. The number on the report matters far less than the context around it.

This article is educational and is not a substitute for individual medical advice.